Default company panoramic image
7e6b4b04 9bcf 4f78 9c99 f71fa9f3c2fa

Glycadia, Inc. aka Glycadia Pharmaceuticals

Glycadia is developing drugs to prevent and treat the kidney, eye, nerve and cardiovascular complications that result from diabetes

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Philadelphia, PA, USA
  • Currency USD
  • Founded April 1988
  • Employees 8
  • Website glycadia.com

Company Summary

Glycadia's drugs target cell-signaling pathways that cause kidney, eye, nerve and cardiovascular complications of diabetes. These drugs are effective independent of glucose control. Currently there are no drugs that effectively halt the progression of complications of diabetes, which remain a significant unmet medical need as well as a major market opportunity. In the U.S. there are 5 million diabetics who have symptoms leading to complications.

Team

  • Default avatar
    Margo P. Cohen
    President and Chief Scientific Officer

    Previously Professor of Medicine and Director of Endocrinology and Metabolism at two urban medical schools. She is a Fulbright Scholar. Principal Investigator in numerous clinical trials for New Drug Applicatons by the pharmaceutical industry. Served on numerous advisory committees of the National Institutes of Health. Twice appointed Chair of the Board of Scientific Counselors of a member NIH Institute. B.S. and M.D. from University of Michigan

  • Default avatar
    Ben F. McGraw
    CEO-to-be upon major funding

    Previously Chairman, President & CEO of Valentis, a public company. Prior: Vice President for Corporate Development for Allergan. Began his career at Marion Laboratories, becoming Vice President, Development. Completed clinical pratice residency and B.S. and Doctor of Pharmachy degrees from the University of Tennessee Center for Health Sciences.

Advisors

  • Default avatar
    Stephen Goodman, Morgan Lewis & Bockius
    Lawyer
    Unconfirmed
    Default avatar
    John Pennett, Eisner Amper
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Genesis Seed Fund, Philadelphia, PA
    Unconfirmed
    Default avatar
    WestMed Medical Ventures, New York, NY
    Unconfirmed
    Default avatar
    Daniel Honigman, Miami, FL
    Unconfirmed